Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C31H41N6O7.Na |
Molecular Weight | 632.683 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 5 / 5 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[Na+].CC(C)C[C@@H]1NC(=O)[C@H](NC(=O)[C@@H]2CCCN2C(=O)[C@@H](CC([O-])=O)NC(=O)[C@@H](CC3=CNC4=CC=CC=C34)NC1=O)C(C)C
InChI
InChIKey=FLIKEIGEOXCRRG-JKNHBXRPSA-M
InChI=1S/C31H42N6O7.Na/c1-16(2)12-21-27(40)33-22(13-18-15-32-20-9-6-5-8-19(18)20)28(41)35-23(14-25(38)39)31(44)37-11-7-10-24(37)29(42)36-26(17(3)4)30(43)34-21;/h5-6,8-9,15-17,21-24,26,32H,7,10-14H2,1-4H3,(H,33,40)(H,34,43)(H,35,41)(H,36,42)(H,38,39);/q;+1/p-1/t21-,22+,23+,24-,26+;/m0./s1
Molecular Formula | C31H41N6O7 |
Molecular Weight | 609.6932 |
Charge | -1 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 5 / 5 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
Molecular Formula | Na |
Molecular Weight | 22.9898 |
Charge | 1 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
BQ-123 is a selective endothelin receptor-1 antagonist; it is used as a biochemical tool in the study of endothelin receptor function. BQ-123 was suspected to contribute to the regulation of vascular tone humans. However, a study involving young normotensive subjects did not demonstrate any major role for BQ-123 regulation of vascular tone.
CNS Activity
Sources: https://www.ncbi.nlm.nih.gov/pubmed/8437512
Curator's Comment: Known to be CNS non-penetrant in rats. Human data not available
Originator
Sources: https://www.ncbi.nlm.nih.gov/pubmed/8809172
Curator's Comment: BQ-123 originally isolated from microbial sources by Banyu investigators
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: P25101|||Q16433 Gene ID: 1909.0 Gene Symbol: EDNRA Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/7690094 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
PubMed
Title | Date | PubMed |
---|---|---|
[Demonstration of a vasopressor role of endogenous endothelin after inhibition of nitric oxide synthesis in rats]. | 1995 Aug |
|
ETA receptor-mediated constrictor responses to endothelin peptides in human blood vessels in vitro. | 1995 May |
|
Endothelin receptor-mediated Ca2+ mobilization and contraction in bovine oviductal arteries: comparison with noradrenaline and potassium. | 1997 Oct |
|
Endothelin-1 binding to endothelin receptors in the rat anterior pituitary gland: possible formation of an ETA-ETB receptor heterodimer. | 2002 Apr |
|
Actions of endothelin and corticotropin releasing factor in the guinea-pig ileum: no evidence for an interaction with capsaicin-sensitive neurons. | 2003 Aug |
|
Endothelin 1 versus endothelin 3 in the development of the slow force response to myocardial stretch. | 2005 Apr |
|
Endothelin-1 receptor antagonist BQ123 prevents pulmonary artery hypertension induced by low ambient temperature in broilers. | 2005 Dec |
|
Cyclo-oxygenase-2, endothelium and aortic reactivity during deoxycorticosterone acetate salt-induced hypertension. | 2005 May |
|
Functional characterization and expression of endothelin receptors in rat carotid artery: involvement of nitric oxide, a vasodilator prostanoid and the opening of K+ channels in ETB-induced relaxation. | 2005 Nov |
|
Modulation of the myocardial effects of selective ETB receptor stimulation and its implications for heart failure. | 2005 Sep |
|
Mechanisms of direct peritoneal resuscitation-mediated splanchnic hyperperfusion following hemorrhagic shock. | 2007 Apr |
|
Central endothelin: effects on vasopressin and the arterial baroreflex in doxorubicin heart failure rats. | 2008 Jun |
|
Selective ET(A) receptor blockade protects against cisplatin-induced acute renal failure in male rats. | 2014 May 5 |
|
BQ-123 prevents LPS-induced preterm birth in mice via the induction of uterine and placental IL-10. | 2015 Feb 1 |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/12049621
double-blind randomized study: 50 nmol/min for 60 min, or 300 nmol/min for 5 min followed by saline for 55 min
Route of Administration:
Intra-arterial
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 11:00:45 GMT 2023
by
admin
on
Sat Dec 16 11:00:45 GMT 2023
|
Record UNII |
05427HSQ1I
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Systematic Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
DBSALT002128
Created by
admin on Sat Dec 16 11:00:45 GMT 2023 , Edited by admin on Sat Dec 16 11:00:45 GMT 2023
|
PRIMARY | |||
|
53229988
Created by
admin on Sat Dec 16 11:00:45 GMT 2023 , Edited by admin on Sat Dec 16 11:00:45 GMT 2023
|
PRIMARY | |||
|
136655-57-7
Created by
admin on Sat Dec 16 11:00:45 GMT 2023 , Edited by admin on Sat Dec 16 11:00:45 GMT 2023
|
PRIMARY | |||
|
05427HSQ1I
Created by
admin on Sat Dec 16 11:00:45 GMT 2023 , Edited by admin on Sat Dec 16 11:00:45 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> SALT/SOLVATE |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |